Group 1 - The independent director Shen Yunqiao has submitted his resignation due to personal reasons, stepping down from multiple positions including independent director and committee roles [2][3] - Shen's resignation will result in a non-compliance with legal and regulatory requirements regarding the proportion of independent directors on the board and its committees [3] - The company will expedite the process of electing a new independent director to ensure compliance with relevant regulations [3] Group 2 - The company has approved a share repurchase plan, allowing for the buyback of shares using funds between RMB 10 million and RMB 20 million, with a maximum repurchase price of RMB 9.53 per share [7] - As of December 2025, the company has repurchased a total of 1,910,214 shares, representing 0.70% of the total share capital, with a total expenditure of RMB 16,138,029.08 [8] - The repurchase activities are in accordance with legal regulations and the company's repurchase plan [9]

Group 1 - The company, Nanxin Pharmaceutical, announced a share buyback program, with a total of 1,910,214 shares repurchased, representing 0.70% of its total share capital of 274,400,000 shares [1] - The highest price for the repurchased shares was 8.92 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount spent on the share buyback was 16,138,029.08 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - Company Nanjing New Pharmaceutical announced a share buyback program, repurchasing approximately 1.91 million shares, which represents 0.7% of the total share capital of about 274 million shares [1] - The highest price for the repurchased shares was 8.92 yuan per share, while the lowest price was 7.02 yuan per share [1] - The total amount spent on the share buyback was approximately 16.14 million yuan [1]

Group 1 - The core point of the article is that Nanjing New Pharmaceutical (688189.SH) has announced a share buyback program, repurchasing a total of 1.9102 million shares, which represents 0.70% of the company's total share capital of 274,400,000 shares [1] - The buyback was conducted through the Shanghai Stock Exchange's centralized bidding trading system [1] - The highest price paid for the repurchased shares was 8.92 yuan per share, while the lowest price was 7.02 yuan per share, with a total expenditure of 16,138,029.08 yuan (excluding stamp duty and transaction commissions) [1]

Group 1 - The core point of the article is that Nanjing Pharmaceutical (688189.SH) has announced a share buyback program, repurchasing a total of 1.9102 million shares, which represents 0.70% of the company's total share capital of 274,400,000 shares [1] - The highest price at which the shares were repurchased was 8.92 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount of funds used for the share buyback was 16,138,029.08 CNY, excluding stamp duty and transaction commissions [1]

Group 1 - The company announced a share repurchase plan starting from April 28, 2025, with an estimated amount of 10 million to 20 million yuan for employee stock ownership plans or equity incentives [1] - As of December 31, 2025, the company has repurchased a total of 1,910,214 shares, accounting for 0.70% of the total share capital, with a total expenditure of 16.138 million yuan [1] - The repurchase in December 2025 involved 952,194 shares, representing 0.35% of the total, with a payment of 8.1402 million yuan at prices ranging from 8.43 yuan to 8.76 yuan per share [1]

证券代码：688189 证券简称：南新制药 公告编号：2026-002 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 湖南南新制药股份有限公司 易日内公告截至上月末的回购进展情况。公司现将回购股份进展情况公告如下： 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,910,214股 | | 累计已回购股数占总股本比例 | 0.70% | | 累计已回购金额 | 16,138,029.08元 | ...

证券代码：688189 证券简称：南新制药 公告编号：2026-001 湖南南新制药股份有限公司 | 是否继续在上市 | 是否存在未 | 原定任期到 | 具体职务 | 姓名 | 离任职务 | 离任时间 | 离任原因 | 公司及其控股子 | 履行完毕的 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 期日 | （如适用） | 公司任职 | 公开承诺 | | | | | | | | | | | | 第 | 二 | 届 | 董 | 事 | 会 | 独立董事、董事 | | | | | | | | | 会 | 审 | 计 | 委 | 员 | 会 | 自公司股东 | 沈云 | 委员、董事会薪 | 会选举产生 | 2026 | 年 | 6 | 月 | | 个人原因 | 否 | 不适用 | 否 | 樵 | 酬 | 与 | 考 | 核 | 委 | 员 | 新任独立董 | 28 | 日 | | 会召集人、董事 | 事之日 | 会 | 提 | 名 | 委 | 员 | 会 | | | | ...

Core Viewpoint - The company announced the resignation of independent director Shen Yunqiao due to personal reasons, effective immediately, and he will no longer hold any position within the company after the resignation [1] Group 1 - Shen Yunqiao has submitted a written resignation report to the board, resigning from his roles as independent director, audit committee member, compensation and assessment committee chair, and nomination committee member [1] - Until a new independent director is elected at the company's shareholders' meeting, Shen Yunqiao will continue to fulfill his responsibilities [1] - As of the announcement date, Shen Yunqiao did not hold any shares in the company [1]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、会议召开和出席情况 （一）股东会召开的时间：2025年12月26日 （二）股东会召开的地点：广东省广州市黄埔区开源大道196号广州南新制药有限公司313会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 证券代码：688189 证券简称：南新制药公告编号：2025-057 湖南南新制药股份有限公司 2025年第二次临时股东会决议公告 ● 本次会议是否有被否决议案：无 审议结果：通过 ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由湖南南新制药股份有限公司（以下简称"公司"）董事会召集，由董事长张世喜先生主持， 会议采用现场投票与网络投票相结合的表决方式进行表决。本次会议的召集、召开程序与表决方法、表 决程序符合《公司法》《公司章程》及《上海证券交易所科创板股票上市规则》等法律、法规和规范性 文件的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事5人，列席5 ...